Avaliação do uso do soro hiperimune Gastroglobulin® como terapia adjuvante na parvovirose canina.

Abstract

The objective of this research was to evaluate the efficacy of hyperimmune serum Gastroglobulin® as an adjuvant therapy against canine parvovirus. Therefore, we used 22 dogs affected with canine parvovirus, detected through the use of Vencofarma Senspert P®. The dogs were of both sexes, different ages, obtained from routine ambulatory care of the Veterinary Hospital (HV) and UFCG center Veterinarian Dr. Leonardo Torres (CMVLT) in Patos-PB. The animals were randomly divided into two groups called the Control Group (CG) and Gastroglobulin Group (GG), an equal number (n = 11). In the animals of CG was adopted standard treatment protocol for canine parvovirus and in Gastroglobulin Group (GG), was added to the standard protocol Gastroglobulin hyperimmune serum at a dose of 01 ml/kg as a single dose subcutaneously. We assessed the level of consciousness, nutritional status, body temperature, heart and respiratory rate, degree of dehydration, mucous, blood count and determination of the viral agent. The numerical data obtained were submitted to analysis of variance (ANOVA) followed by Tukey test (p <0,05). As for the clinical manifestations observed during the period of hospitalization of the animals are consistent with the manifestation reported in the research literature about the disease. Were also not found statistical differences between groups, as well as group over the evaluation moments, among haematological variables analyzed. The leukocyte count, the averages of the variables studied are within the normal range for the species. It was concluded at the end of this research that the adoption of the use of hyperimmune serum as adjuvants in fighting canine parvovirus not show through the methodological criteria used in this assessment, benefits to the animals in recovery resulting from its use.